Skip to main content
. 2016 Apr 6;15(12):1552–1557. doi: 10.1080/15384101.2016.1164372

Figure 1.

Figure 1.

The HNRNPK gene is lost in a subset of de novo AML patients. (Left) Functional validation of the control probe (RP11-19G1, green) to the distal arm of chromosome 9p and HNRNPK probe (RP11-101L4, red) to the 9q21.32 locus using metaphase FISH on haematopoietic cells from healthy donors. DAPI is used as a counterstain to denote the DNA (chromosomes). (Middle). Nuclei of an interphase haematopoietic cell isolated from the bone marrow of a healthy donor indicating two HNRNPK alleles on chromosome 9 (two red/2 green). DAPI is used as a counterstain to denote the nucleus. (Right). Nuclei of an interphase haematopoietic cell isolated from the bone marrow of a de novo AML patient with haploinsufficient loss of the HNRNPK gene (one red/2 green). DAPI is used as a counterstain to denote the nucleus.